Neuroleptic malignant syndrome (NMS)
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
Medication-Induced MovementG21.0
Loading…
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
≥3 of 12 catatonia symptoms: stupor; catalepsy; waxy flexibility; mutism; negativism; posturing; mannerism; stereotypy; agitation; grimacing; echolalia; echopraxia
Persistent deficits in social communication/interaction across multiple contexts (≥3 components: social-emotional reciprocity; nonverbal communicative behaviours; developing/maintaining relationships)
≥1 full manic episode (abnormally elevated/expansive/irritable mood + ↑energy, ≥7 days or any duration if hospitalised)
≥1 of: delusions; hallucinations; disorganised speech; grossly disorganised/catatonic behaviour
≥5 of 9 SIG-E-CAPS symptoms for ≥2 weeks; ≥1 must be depressed mood or anhedonia
Uninterrupted period of illness including a major mood episode (MDE or manic) concurrent with Schizophrenia Criterion A symptoms
≥2 of: delusions; hallucinations; disorganised speech; grossly disorganised/catatonic behaviour; negative symptoms — ≥1 must be delusions, hallucinations, or disorganised speech
Same symptom criteria as Schizophrenia (≥2 of the 5 symptom clusters; ≥1 must be delusions, hallucinations, or disorganised speech)